The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement

Renato G. Martins, Thomas A. D'Amico, Billy W. Loo, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng Ming Kong, Mark G. Kris, Inga T. Lennes, Douglas E. Wood

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Patients with stage IIIA non-small cell lung cancer, determined based on involvement of ipsilateral mediastinal lymph nodes, represent the most challenging management problem in this disease. Patients with this stage disease may have very different degrees of lymph node involvement. The pathologic confirmation of this involvement is a key step in the therapeutic decision. The difference in the degree of lymph node compromise has prognostic and treatment implications. Based on multiple considerations, patients can be treated with induction chemotherapy, chemoradiotherapy followed by surgery, or definitive chemoradiotherapy without surgery. Data derived from clinical trials have provided incomplete guidance for physicians and their patients. The best therapeutic plan is achieved through the multidisciplinary cooperation of a team specialized in lung cancer.

Original languageEnglish (US)
Pages (from-to)599-613
Number of pages15
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Lymph Nodes
Chemoradiotherapy
Induction Chemotherapy
Lung Neoplasms
Therapeutics
Clinical Trials
Physicians

ASJC Scopus subject areas

  • Oncology

Cite this

Martins, R. G., D'Amico, T. A., Loo, B. W., Pinder-Schenck, M., Borghaei, H., Chaft, J. E., ... Wood, D. E. (2012). The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. JNCCN Journal of the National Comprehensive Cancer Network, 10(5), 599-613. https://doi.org/10.6004/jnccn.2012.0062

The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. / Martins, Renato G.; D'Amico, Thomas A.; Loo, Billy W.; Pinder-Schenck, Mary; Borghaei, Hossein; Chaft, Jamie E.; Ganti, Apar Kishor P.; Kong, Feng Ming; Kris, Mark G.; Lennes, Inga T.; Wood, Douglas E.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 10, No. 5, 01.05.2012, p. 599-613.

Research output: Contribution to journalReview article

Martins, RG, D'Amico, TA, Loo, BW, Pinder-Schenck, M, Borghaei, H, Chaft, JE, Ganti, AKP, Kong, FM, Kris, MG, Lennes, IT & Wood, DE 2012, 'The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 5, pp. 599-613. https://doi.org/10.6004/jnccn.2012.0062
Martins, Renato G. ; D'Amico, Thomas A. ; Loo, Billy W. ; Pinder-Schenck, Mary ; Borghaei, Hossein ; Chaft, Jamie E. ; Ganti, Apar Kishor P. ; Kong, Feng Ming ; Kris, Mark G. ; Lennes, Inga T. ; Wood, Douglas E. / The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. In: JNCCN Journal of the National Comprehensive Cancer Network. 2012 ; Vol. 10, No. 5. pp. 599-613.
@article{c54e9f40dff64bf3a6892c6b073636dd,
title = "The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement",
abstract = "Patients with stage IIIA non-small cell lung cancer, determined based on involvement of ipsilateral mediastinal lymph nodes, represent the most challenging management problem in this disease. Patients with this stage disease may have very different degrees of lymph node involvement. The pathologic confirmation of this involvement is a key step in the therapeutic decision. The difference in the degree of lymph node compromise has prognostic and treatment implications. Based on multiple considerations, patients can be treated with induction chemotherapy, chemoradiotherapy followed by surgery, or definitive chemoradiotherapy without surgery. Data derived from clinical trials have provided incomplete guidance for physicians and their patients. The best therapeutic plan is achieved through the multidisciplinary cooperation of a team specialized in lung cancer.",
author = "Martins, {Renato G.} and D'Amico, {Thomas A.} and Loo, {Billy W.} and Mary Pinder-Schenck and Hossein Borghaei and Chaft, {Jamie E.} and Ganti, {Apar Kishor P.} and Kong, {Feng Ming} and Kris, {Mark G.} and Lennes, {Inga T.} and Wood, {Douglas E.}",
year = "2012",
month = "5",
day = "1",
doi = "10.6004/jnccn.2012.0062",
language = "English (US)",
volume = "10",
pages = "599--613",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement

AU - Martins, Renato G.

AU - D'Amico, Thomas A.

AU - Loo, Billy W.

AU - Pinder-Schenck, Mary

AU - Borghaei, Hossein

AU - Chaft, Jamie E.

AU - Ganti, Apar Kishor P.

AU - Kong, Feng Ming

AU - Kris, Mark G.

AU - Lennes, Inga T.

AU - Wood, Douglas E.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Patients with stage IIIA non-small cell lung cancer, determined based on involvement of ipsilateral mediastinal lymph nodes, represent the most challenging management problem in this disease. Patients with this stage disease may have very different degrees of lymph node involvement. The pathologic confirmation of this involvement is a key step in the therapeutic decision. The difference in the degree of lymph node compromise has prognostic and treatment implications. Based on multiple considerations, patients can be treated with induction chemotherapy, chemoradiotherapy followed by surgery, or definitive chemoradiotherapy without surgery. Data derived from clinical trials have provided incomplete guidance for physicians and their patients. The best therapeutic plan is achieved through the multidisciplinary cooperation of a team specialized in lung cancer.

AB - Patients with stage IIIA non-small cell lung cancer, determined based on involvement of ipsilateral mediastinal lymph nodes, represent the most challenging management problem in this disease. Patients with this stage disease may have very different degrees of lymph node involvement. The pathologic confirmation of this involvement is a key step in the therapeutic decision. The difference in the degree of lymph node compromise has prognostic and treatment implications. Based on multiple considerations, patients can be treated with induction chemotherapy, chemoradiotherapy followed by surgery, or definitive chemoradiotherapy without surgery. Data derived from clinical trials have provided incomplete guidance for physicians and their patients. The best therapeutic plan is achieved through the multidisciplinary cooperation of a team specialized in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84861830553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861830553&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2012.0062

DO - 10.6004/jnccn.2012.0062

M3 - Review article

VL - 10

SP - 599

EP - 613

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 5

ER -